Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mary Reynolds

Physician Assistant West Union, SC Physician Assistant

NPI 1417174673 CMS profile 10865203

1205 N Highway 11, West Union, SC 29696

Open in the dashboard

General payments

$4,984

328 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Reynolds of West Union, SC is reported in the CMS Open Payments database as having received $4,984 across 328 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $896 55
2024 General $916 59
2023 General $884 54
2022 General $904 62
2021 General $1,384 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Reynolds
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Mary Reynolds were reported at $896. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Mary Reynolds Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,384 $132 $37–$438 $132
2022 $904 $155 $48–$522 $149
2023 $884 $167 $52–$557 $160
2024 $916 $178 $55–$600 $164
2025 $896 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $994 89 payments
  2. Lilly USA, LLC $436 27 payments
  3. Otsuka America Pharmaceutical, Inc. $386 20 payments
  4. Amgen Inc. $379 22 payments
  5. AstraZeneca Pharmaceuticals LP $357 22 payments
  6. Novo Nordisk Inc $308 19 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $221 16 payments
  8. GlaxoSmithKline, LLC. $195 13 payments
  9. Nestle HealthCare Nutrition Inc. $158 12 payments
  10. Lundbeck LLC $104 6 payments
  11. Other $1,447 82 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,984 328 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $647 59 payments
  2. REXULTI $386 20 payments
  3. Ozempic $308 19 payments
  4. RYBELSUS $286 18 payments
  5. MOUNJARO $244 15 payments
  6. AIMOVIG $223 10 payments
  7. XIFAXAN $221 16 payments
  8. VRAYLAR Neuroscience $190 18 payments
  9. Repatha $184 14 payments
  10. TRELEGY ELLIPTA $183 12 payments
  11. Other $3,069 190 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 95 drugs

Part D claims

4,074

Median for Physician Assistant: 241

Drug cost

$306,006

Median for Physician Assistant: $4,110

Branded share of claims

18.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 53 $64,762
Ozempic Semaglutide Brand 40 $36,696
Xarelto Rivaroxaban Brand 23 $30,139
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 21 $23,010
Trulicity Dulaglutide Brand 20 $20,733
Eliquis Apixaban Brand 26 $19,435
Jardiance Empagliflozin Brand 25 $18,160
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 26 $17,527
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 14 $9,655
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $9,236

The 10 drugs with the highest cost, of 95 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $140
$140 — —
MOUNJARO
  • Lilly USA, LLC $84
$84 53 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $68
  • Lundbeck LLC $13
$81 — —
Auvelity
  • Axsome Therapeutics, Inc. $69
$69 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

328 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record